Skip to content

Molecular Mechanisms of Raspberries Effect on Insulin Resistance and Inflammation

Molecular Mechanisms Underlying the Protective Effects of Whole Red Raspberries Against Insulin Resistance and Inflammation in Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04306406
Acronym
RASPBERRY
Enrollment
9
Registered
2020-03-12
Start date
2015-01-07
Completion date
2017-01-13
Last updated
2020-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Insulin Resistance

Brief summary

Red raspberries (Rubus idaeus) are a good source of health enhancing hydrolyzable and condensed tannins, flavonoids, anthocyanins, phenolic acids, rheosmin, potassium, carotenoids, vitamin C, and vitamin K1. Compared to other berries commonly consumed in the US, the health benefits of red raspberries to improve pre-diabetes mellitus (PDM) and type 2 diabetes have never been explored. The clinical study proposed in this project seeks to investigate the protective effect of whole red raspberries against insulin resistance, oxidative stress, and inflammation in PDM and type 2 diabetic patients. The in vitro study proposed in the project will assist in identifying the molecular mechanisms by which whole red raspberry protect islet cells against oxidative stress, insulin resistance and loss of cell function.

Interventions

Red raspberry smoothies drink

Sponsors

National Processed Raspberry Council
CollaboratorUNKNOWN
Louisiana State University and A&M College
CollaboratorOTHER
Pennington Biomedical Research Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* type 2 diabetes

Exclusion criteria

* hypoglycemic agents * Pregnant or nursing a child * chronic medication that does not have a stable dose for greater than one month * anti-inflammatory medication * inflammatory disease

Design outcomes

Primary

MeasureTime frameDescription
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)2 weeksRatio of fasting insulin and glucose
A high-sensitivity C-reactive protein (hs-CRP) measured in milligrams per liter2 weeksMeasure of systemic inflammation

Secondary

MeasureTime frameDescription
3,4-Dihydroxyphenylacetic acid (DOPAC) measured in nanograms per milliliter2 weeksMeasure of systemic inflammation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026